menu
Robert W. Holloway, MD
Robert W. Holloway , MD
Medical Director (Gyn Onc), Gynecologic Oncologist
Cancer
Overview
Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.
Articles
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for <i>BRCA</i> wild-type, platinum-sensitive, recurrent ovarian cancer
CANCER
2024
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
Gynecologic oncology
2024
Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024
Standardized Titration Protocol Reduces the Incidence of Paclitaxel Infusion-Related Hypersensitivity Reactions
JCO ONCOLOGY PRACTICE
2023
Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation
LIFE SCIENCES
2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Gynecologic oncology
2023
Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
ANNALS OF ONCOLOGY
2023
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I endometrial cancer
Gynecologic oncology
2023
Clinical outcomes analysis of neoadjuvant chemotherapy for locally advanced vulvar cancer
Gynecologic oncology
2023
Immunotherapy response monitoring using personalized circulating tumor DNA analysis in patients with relapsed gynecologic malignancies
Gynecologic oncology
2023
Education & Training
Education
Vanderbilt University Medical Center
Residency
University of Alabama Birmingham
Fellowship
Georgetown University Hospital
Specialty
Gynecology Oncology
Board Certifications
American Board of Obstetrics & Gynecology